Why IMU is a multi multi bagger, page-4371

Thanks @Watmighthavben for your well constructed and thoughtful posts. Much appreciated. I am excited about IMU's prospects.

I read your post today, 7 Nov 2021, and you mentioned to refer to your previous posts about TIGIT which I am not familiar with as yet. So I went back through your posts and found the one you may be referring to.

Here is an extract from the post:
"In ongoing studies, Kaumaya and his team have ascertained that (PD-L1-Vaxx), when combined with the B-cell epitope-specific vaccine B-Vaxx, shows synergistic activities. They have developed several syngeneic cancer models to test their various combination immunotherapies. Finally, they are developing vaccines for CTLA-4, TIM3, LAG3 and TIGIT that will form a combination immunotherapeutic platform for developing cancer cures."

I looked up the IMU website and wasn't able to find any reference to TIGIT.
I am wondering whether IMU has IP access to these later research studies by Dr. Kaumaya under existing agreements or whether because of the existing relationship it may be likely to follow.

Would appreciate your thoughts on this. Thanks in advance.